HomeAI · summaries
Storia in 2 fonti
FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and rivoceranib at the FDA. | The third time is not the charm for Hengrui Pharma and Elevar Therapeutics. The pair’s star-crossed cancer drug combination of camrelizumab and rivoceranib has been rejected by the FDA for the third time.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and rivoceranib at the FDA. | The third time is not the charm…
- ·
endpoints.news
FDA rejects Hengrui-Elevar liver cancer drug combo for third time
FDA rejects Hengrui and Elevar Therapeutics' liver cancer combo for a third time, citing new manufacturing issues.